A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
Completed · Phase 3 · NCT06471361
Conditions: Generalized Myasthenia Gravis
At a glance
- Research payments reported, 2025
- $286,751
- U.S. investigators named
- 7
- Sites paid
- 8
- Planned or actual enrollment
- 31
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Zilucoplan (drug)
- Dates
- Started 2024-08-27; completion 2025-02-03
- Results posted
- Yes
The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.
From ClinicalTrials.gov, last updated 2026-03-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $286,751 in research payments for this study in 2025 (9 payments).
Products named: Zilbrysq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Richard J. Nowak, M.D. Neurology · New Haven, CT
- Tuan H. Vu, MD Neurology · Tampa, FL
- Syed A. Shah, M.D Neurology · Columbia, MO
- James Howard, MD Neurology · Chapel Hill, NC
- Mary E. Petrulis, MD Neurology · Columbus, OH
- Yessar M. Hussain, M.D. Physical Medicine & Rehabilitation (PM&R) · Austin, TX
- Bhupendra O. Khatri, M.D. Neurology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $85,946
- The Ohio State University $68,130
- University of Missouri Health Care, MO $44,504
- UC Irvine Medical Center- Als & Neuromuscular Center $24,243
- West Haven VA Medical Center $18,934
- National Neuromuscular Research Institute, PLLC $18,312
- University of North Carolina at Chapel Hill $18,068
- Bcn Research LLC $8,614
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.